Nadroparin Calcium

Nadroparin calcium

Names
Trade names	Fraxiparin(e), Fraxodi, others
IUPAC name (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
Clinical data
Routes of use	Subcutaneous injection (except for haemodialysis)
External links
AHFS/Drugs.com	International Drug Names
Legal
Legal status	AU: S4 (Prescription only) CA: ℞-only
Pharmacokinetics
Bioavailability	89% (SC dose)
Elimination half-life	3.7 hours (SC dose)
Excretion	clearance 21.4mL/min (+/- 7)
Chemical and physical data
Molar mass	4300 g/mol

Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.^[1] It is given by injection under the skin.

It is in the low molecular weight heparin (LMWH) class.

It is on the World Health Organization's List of Essential Medicines as an alternative to enoxaparin.^[2]

History[edit | edit source]

Nadroparin was developed by Sanofi-Synthélabo.

References[edit | edit source]

External links[edit | edit source]

• "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Archived from the original on 10 August 2019. Retrieved 2 April 2019.
• Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417. S2CID 95878036.

This drug article relating to the blood and blood forming organs is a stub. You can help MDWiki by expanding it.

• v
• t
• e